Trials / Sponsors / Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Industry · 4 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | 2025-05-26 |
| Terminated | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Metastatic Breast Cancer, HER2-positive Breast Cancer | Phase 2 | 2023-11-30 |
| Terminated | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer | Phase 1 | 2023-10-11 |
| Terminated | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Exp HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer | Phase 1 / Phase 2 | 2020-02-24 |